Monitoring Cardiovascular Medicine Prices as a Tool for Analyzing the Effectiveness of Government Intervetions to Ensure Access to Medicines at the Regional Level

Aim. The aim of our study was to continue a comparative analysis of availability and access to cardiovascular medicines in 2017 and 2018 in the city of Kazan according to the original WHO/HAI methodology to assess the effectiveness of government interventions to ensure access to medicines.
Material and methods. We performed a comparative analysis of prices of cardiovascular medicines in 2017 and 2018 in Kazan using the World Health Organization and Health Action International (WHO/HAI) methodology, to assess medicines' availability and affordability to ensure their rational use. We studied availability and prices of 71 cardiovascular medicines in public and private pharmacies in the city of Kazan and analyzed procurement prices of these medicines in hospitals. Also we studied the affordability of medicines, as well as performed pharmacoeconomic cost-minimization analysis for arterial hypertension pharmacotherapy in 2018. For each name, we studied the prices for the original brand and its lowest-priced generic. We compared medicine prices with international reference, delivered by the Management Sciences for Health and by expressing them as median price ratio (MPR).
Results. In the public sector, prices of generic medicines were at the level of reference prices with the indicators of MPR 1.14 [0.41-1.84] and 1.17 [0.49-2.21], in 2017 and 2018 respectively. In the private sector, prices of generics reduced 2 times in 2018 compared to 2017, with the decrease in MPR from 2.22 [1.12-3.91] to 1.25 [0.44-2.32], (p<0.05). In the public sector, the affordability indicators of generics were the same in the studied years (Me=0.24 in 2017 and Me=0.26 in 2018). However, in the private sector there was a 2.5 times reduction in the affordability of generics (reduction Me from 0.66 to 0.24, p<0.05) in 2018 compared to 2017. From 2017 to 2018 the affordability of original brands changed from 1.9 to 1.3 in the public sector and from 2.3 to 1.5 in the private sector, but this change was not statistically significant (p>0.05). In 2018, depending on the choice of the medicine the annual course of therapy of hypertension varied from 149 to 28835 rubles.
Conclusions. In 2018, the prices of generic cardiovascular medicines, but not of originator brands, reached the level of reference prices in both the public and private sectors of Kazan. According to the WHO/HAI methodology, generic cardiovascular medicines became affordable. In the private sector, there was a reduction in the prices of generic medicines, but not of originator brands, with an improvement of affordability of generics in 2018 compared to 2017.

1. Yusuf S., Islam S., Chow C.K., et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE study): a prospective epidemiological survey. Lancet. 2010;378:1231-43. DOI:10.1016/S0140-6736(11)61215-4.

2. WHO Global Action Plan for the prevention and control of noncommunicable diseases 2013-2020. Geneva: World Health Organization, 2013 [cited by October 23, 2019]. Available from: http://apps.who.int/iris/bitstream/10665/94384/1/9789241506236_eng.pdf.

3. Khatib R., McKee M., Shannon H., et al. Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data. Lancet. 2016;387:61-9. DOI:10.1016/S0140-6736(15)00469-9.

4. Murphy A., Palafox B., O'Donnell O., et all. Inequalities in the use of secondary prevention of cardiovascular disease by socioeconomic status: evidence from the PURE observational study. Lancet Glob Health. 2018;6:e292-301. DOI:10.1016/S2214-109X(18)30031-7.

5. Health Action International. Measuring Medicine Prices, Availability, Affordability and Price Components (2nd Edition) [cited by Oct 23, 2019]. Available from: https://haiweb.org/what-we-do/price-availability-affordability/.

6. Razzakova Ch.M., Ziganshina L.E. Change in in affordability of medication in Kazan in 2010 and 2015 as a reflection of state initiatives to regulate drug prices. Kazan Medical Journal. 2017;5:8226. (In Russ.)

7. Imaeva A.E., Balanova Y.A., Kontsevaya A.V., et al. Availability and Affordability of Medicines for the Treatment of Cardiovascular Diseases in Pharmacies in Six Regions of the Russian Federation. Rational Pharmacotherapy in Cardiology. 2018;14(6):804-15 (In Russ.) DOI:10.20996/1819-6446-2018-14-6-804-815.

8. Razzakova Ch.M., Ziganshina L.E. Cardiovascular medicine prices as an indicator of access to medicines and their rational use. Rational Pharmacotherapy in Cardiology. 2019;15(2):215-23 (In Russ.). DOI:10.20996/1819-6446-2019-15-2-215-223.

9. Decree of the Government of the Russian Federation of October 29, 2010 N 865 "State regulation of prices for drugs included in the list of vital and essential medicines [cited by October 23, 2019]. Available from: https://www.rosminzdrav.ru/documents/7459-postanovlenie-pravitelstva-rf-865 (In Russ.)

10. Decree of the Government of Russia of April 15, 2013 N 305 “On the federal target program “Development of the pharmaceutical and medical industry of the Russian Federation for the period up to 2013-2020” [cited by October 23, 2019]. Available from: http://minpromtorg.gov.ru/docs/#!42298 (In Russ.)

11. Decree of the Government of the Russian Federation of September 15, 2015 N 979 “On Amendments to the Decree of the Government of the Russian Federation of October 29, 2010 N 865” On state regulation of prices for medicines included in the list of vital and essential medicines [cited by October 23, 2019]. Available from: http://government.ru/docs/19739/ (In Russ.)

12. International Drug Price Indicator Guide [cited by October 23, 2019]. Available from: http://msh-priceguide.org/en/home/.

13. Ziganshina L.E., Lepekhina V.K., Petrov V.I., Khabrieva R.Y., eds. Large reference book of medicines. Moscow: GEOTAR-Media; 2011 (In Russ.)

14. Federal Law “On the Minimum Wage of 06/19/2000 No. 82-FZ”. The collection of legislation of the Russian Federation of 2000, No. 26, Art. 2729 [cited by October 23, 2019]. Available from: http://www.pravo.gov.ru/proxy/ips/?docview&page=1&print=1&nd=102066375&rdk=17&&empire= (In Russ.)

15. Jagudina R.I., Serpik V.G. Cost analysis methodology. Pharmacoeconomics: Theory and Practice.2016;4(2):5-9 (In Russ.)

16. Arterial hypertension in adults. Clinical guidelines; 2019 [cited by October 23, 2019] Available from: http://cr.rosminzdrav.ru/#!/recomend/687 (In Russ.)

17. Federal Antimonopoly Service. Competition Report 2015 [cited by Oct 23, 2019]. Available from: https://fas.gov.ru/documents/589902 (In Russ.)

18. Decree of the Government of the Russian Federation of November 28, 2013 N 1086 “On approval of the Rules for the formation of the list of medicines, the purchase of which is carried out in accordance with their trade names” [cited by Oct 23, 2019]. Available from: http://government.ru/docs/8598/ (In Russ.)

19. Wirtz V.J., Hogerzeil H.V., Gray A.L., et al. Essential medicines for universal health coverage. Lancet. 2017;389(10067):403-76. DOI:10.1016/S0140-6736(16)31599-9.